Navigation Links
Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
Date:10/24/2013

TARRYTOWN, N.Y., Oct. 24, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey for the second year in a row.  This distinction will be celebrated Monday, October 28, in conjunction with a groundbreaking ceremony for two new buildings to be constructed at the Regeneron campus in Westchester County, New York.

U.S. Senator Charles E. Schumer, U.S. Rep. Nita Lowey, Empire State Development Corp. President & CEO Kenneth Adams, and other public officials are scheduled to participate in an event with Regeneron employees that will celebrate the biotechnology company's latest expansion and the emergence of the lower Hudson Valley as a life sciences cluster.

"Regeneron's tremendous growth and our current expansion plans are undoubtedly thanks to our employees.  If we are the best place to work, it is because we have the best employees and a culture where they feel empowered and challenged," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.
George D. Yancopoulos, Chief Scientific Officer and President, Regeneron Laboratories, said,  "As we are a company founded on scientific excellence, it is very meaningful to us to be recognized by Science magazine two consecutive years now as the top place to work in the industry." 

The new facilities, for which site preparation is underway, will include a total of 300,000 square feet of laboratory and office space, with a projected move-in date of third quarter 2015.  The expansion will increase Regeneron's square footage on the campus by more than 40 percent and make it possible for Regeneron to create approximately 400 new full-time jobs in Westchester, where it currently employs more than 1,500.  With a total of over 2,200 employees, including nearly 700 in the Regeneron Industrial Operations and Product Supply group in Rensselaer, New York near Albany, Regeneron is the largest biotechnology company in New York State and one of the five largest in the world by market capitalization.

The 2013 Science survey sought to identify the companies with the best reputations as employers, based on 3,656 survey responses from readers of Science and other survey invitees.  Survey participants came from North America (81%), Europe (10%), and Asia/Pacific Rim (7%); over 80% worked in private industry.  Details of the rankings and survey results can be found in sciencecareers.org and will be featured in the October 25, 2013 print issue. 

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications914.847.512914.847.764manisha.narasimhan@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
2. Regeneron Announces March 2012 Investor Conference Presentations
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
5. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
8. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
9. Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award
10. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
11. Sequenom Named to NASDAQ Global Select Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Maryland (PRWEB) , ... February 08, 2016 , ... Information ... BSI Web product. The upgrade represents a completely new technical foundation and is ... will offer a responsive design interface, significantly increased speed for search results, a streamlined ...
(Date:2/8/2016)... active R&D program for the development of future natural products ... unique research and development center in Israel ... Stockton has a variety of products ... is active in more than 35 counties worldwide. ... flagship product Timorex Gold ® is used to ...
(Date:2/6/2016)... ... 06, 2016 , ... Contact:, Abby Mitchell, Communications Manager, Phone: ... Sponsors Teacher Training Program , Bite of Science Dinner Event to Strengthen Science ... in Education (CEE) will sponsor a Bite of Science professional enrichment session, cost-free, ...
(Date:2/5/2016)... SAN FRANCISCO , February 5, 2016 ... AMBS), a biotechnology company focused on developing products ... it has requested Rare Pediatric Disease Designation (RPDD) from ... retinitis pigmentosa (RP) with MANF. MANF was previously granted ... December 2014. --> Amarantus BioScience Holdings, Inc. ...
Breaking Biology Technology:
(Date:1/15/2016)... Puerto Rico , Jan. 15, 2016 ... big and small to find new ways to ensure ... culture. iOS and Android ... based on biometrics, transforming it into a hardware authorization ... that users swipe their fingerprint on their KodeKey enabled ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the leading ... 10,000 retail locations, web and mobile, today announced ... million from existing investors. --> ... devoted to further innovate higi,s health platform – ... web portal – including expanding services and programs ...
(Date:1/7/2016)... , Jan. 7, 2016 Various ... for biopharmaceutical products such as biologics and biosimilars. ... to reduce healthcare expenditure, growing demand for cost-effective ... aging population. Biosimilars are similar versions of their ... regards to their quality, safety, and efficacy. The ...
Breaking Biology News(10 mins):